The Use of the Prevena Incision Management System (PIMS) on Closed Incisions in Renal Transplant Subjects

NCT ID: NCT01341444

Last Updated: 2024-10-16

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: NA
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2016-05-31

Brief Summary

This study is being conducted to see how safe and effective the Prevena Incision Management System "Prevena" is when placed over a renal transplantation incision. Prevena provides negative pressure (suction) wound therapy. Prevena will be tested while applied during the time each subject is hospitalized and up to 5 days after the surgery. Prevena is a small portable negative pressure device which consists of a therapy unit that delivers negative pressure. It also includes a dressing system that is intended for use over closed incisions after surgery.

The intent of this study is to evaluate Prevena versus the standard care that a doctor would use normally after a kidney transplant.

Detailed Description

This is a randomized, single-center, comparative interventional study looking at the effect of Prevena™ on renal transplant surgical Subjects compared to a control arm treated with the standard-of-care wound dressing. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of PrevenaTM in this clinical indication.

Conditions

Surgical Site Reaction

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Prevena Incision Management System

Negative Pressure Therapy Device

Group Type: EXPERIMENTAL

Prevena Incision Management System

Intervention Type: DEVICE

It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).

Standard of Care for Surgical Incisions

Sterile gauze and a non-penetrable barrier

Group Type: PLACEBO_COMPARATOR

Standard of Care for Surgical Incisions

Intervention Type: OTHER

Sterile 4X4 Non-Penetrable barrier

Interventions

Prevena Incision Management System

It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).

Intervention Type: DEVICE

Standard of Care for Surgical Incisions

Sterile 4X4 Non-Penetrable barrier

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

The Subject:

1. is an adult ≥ 18 years old of either gender

2. is able to provide their own informed consent Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 6 of 71

3. will undergo open renal transplant surgery within the next 30 days

4. will require a surgical incision able to be covered completely by the PIMS dressing

5. is pre-operatively assessed to undergo a procedure with a CDC Wound Classification of:

1. Class I (Clean): An uninfected operative wound in which no inflammation is encountered and the respiratory, alimentary, genital, or uninfected urinary tract is not entered

• OR -

2. Class II (Clean Contaminated): An operative wound in which the respiratory, alimentary, genital, or uninfected urinary tract are entered under controlled conditions and without unusual contamination

6. is willing and able to return for all scheduled and required study visits

7. if female, must test negative on serum pregnancy test

8. if a female of child-bearing potential, must be willing to utilize an acceptable method of birth control (e.g., birth control pills, condom with spermicide, diaphragm with spermicide, implants, IUD, injections, vaginal rings, hormonal skin patch, etc.) for the duration of study participation

9. is not concurrently enrolled in a clinical trial which may impact subject health or the surgical incision site

The Subject:

2. has undergone a Class I or II CDC Wound Classification procedure resulting in a closed surgical incision able to be covered completely by the PIMS dressing

Exclusion Criteria

The Subject:

1. has a BMI < 18.5 kg/m2 and > 40 kg/m2

2. has a systemic infection at the time of open renal transplant surgery

3. has a remote-site skin infection at the time of open renal transplant surgery

4. is preoperatively assessed to undergo a procedure with a CDC Wound Classification of:

1. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract

• OR -

2. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera

5. has a known allergy or hypersensitivity to silver, or drape materials that contain acrylic adhesives

The Subject:

2. has obvious contamination of the surgical incision

3. requires external surgical drains that will be covered by the PIMS dressing

4. is determined to have a CDC Wound Classification of:

1. Class III (Contaminated): Open, fresh, accidental wounds, and/or major breaks in sterile technique or gross spillage from the gastrointestinal tract

• OR -

2. Class IV (Dirty-Infected): Old traumatic wounds with retained devitalized tissue and those that involve existing clinical infection or perforated viscera Protocol: AHS.2012.Prevena.Cooper.01 v 4.0 Confidential/Property of KCI USA, Inc. Page 8 of 71

5. requires a transfusion, has disseminated-intravascular coagulopathy (DIC) or other medical or surgical conditions during open renal transplant surgery deemed by the Investigator to pose a prohibitively high risk for surgical re-exploration

6. is deemed unable to continue in the study by the Investigator as the Subject's safety or well-being may be jeopardized.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

KCI USA, Inc

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Matthew Cooper, MD

Role: PRINCIPAL_INVESTIGATOR

MedStar Georgetown University Hospital

Locations

MedStar Georgetown University Hospital

Washington D.C., District of Columbia, United States

Countries

United States

Other Identifiers

AHS.2012.Prevena.Cooper.01

Identifier Type: -

Identifier Source: org_study_id